IL-31 Antibody | 3747

IL-31 Antibody | 3747 | Gentaur UK, US & Europe Distribution

Host: Rabbit

Reactivity: Human

Homology: N/A

Immunogen: IL-31 antibody was raised against a 18 amino acid synthetic peptide from near the center of human IL-31.
The immunogen is located within amino acids 60 - 110 of IL-31.

Research Area: Signal Transduction

Tested Application: E, WB, IF

Application: IL-31 antibody can be used for the detection of IL-31 by Western blot at 2.5 - 10 μg/mL. Despite its predicted size, IL-31 runs at approximately 27 - 30 kDa in SDS-PAGE. For immunofluorescence start at 20 μg/mL.
Antibody validated: Western Blot in human samples and Immunofluorescence in human samples. All other applications and species not yet tested.

Specificiy: N/A

Positive Control 1: Cat. No. 1375 - Human Skeletal Muscle Tissue Lysate

Positive Control 2: N/A

Positive Control 3: N/A

Positive Control 4: N/A

Positive Control 5: N/A

Positive Control 6: N/A

Molecular Weight: N/A

Validation: N/A

Isoform: N/A

Purification: IL-31 Antibody is affinity chromatography purified via peptide column.

Clonality: Polyclonal

Clone: N/A

Isotype: IgG

Conjugate: Unconjugated

Physical State: Liquid

Buffer: IL-31 Antibody is supplied in PBS containing 0.02% sodium azide.

Concentration: 1 mg/mL

Storage Condition: IL-31 antibody can be stored at 4˚C for three months and -20˚C, stable for up to one year. As with all antibodies care should be taken to avoid repeated freeze thaw cycles. Antibodies should not be exposed to prolonged high temperatures.

Alternate Name: IL-31 Antibody: 1700013B14Rik, Interleukin-31, IL-31

User Note: Optimal dilutions for each application to be determined by the researcher.

BACKGROUND: IL-31 Antibody: Interleukin-31 (IL-31) is a recently discovered T-cell cytokine closely related to IL-6 type cytokines and is preferentially produced by T helper type 2 cells. IL-31 activity is mediated through the ligand-induced oligomerization of a dimeric receptor complex containing IL-31 receptor A and oncostatin M receptor. In response to IL-31 binding, these proteins activate the JAK/STAT and the AKT signaling pathways. RNA levels of IL-31 receptor A and oncostatin M receptor are induced in activated monocytes but are expressed constitutively in epithelial cells. IL-31, when overexpressed in transgenic mice, results in the development of pruritis, alopecia, and skin lesions and in humans may result in atopic dermatitis, suggesting that IL-31 may represent a novel target for antipruritic drug development.